CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$4.05
-1.70% today
Updated 2026-04-29
Market cap
$951.18M
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-0.15
Dividend yield
—
52W range
$1 – $8
Volume
7.6M
CytomX Therapeutics Inc (CTMX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$4.05
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$14.23
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 2.18% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -22.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.